. Author manuscript; available in PMC: 2016 Jun 23.

Published in final edited form as: Blood Purif. 2016 Mar 31;42(1):33–43. doi: 10.1159/000442741

Table 4. Anemia management decisions, by Hgb categories in the China DOPPS.

Hemoglobin, g/dl^a	ESA use, OR (95% CI)	ESA dose^a, β (95% CI)	Branded ESA use (vs. domestic)^c, OR (95% CI)	IV Iron use^b, OR (95% CI)
<9	1.03 (0.50–2.12)	1,204 (249 to 2,159)	1.04 (0.75–1.44)	1.22 (0.94–1.59)
9–<10	0.84 (0.43–1.65)	598 (−559 to 1,755)	0.83 (0.53–1.30)	1.02 (0.77–1.36)
10–12	1 (ref.)	0 (ref.)	1 (ref.)	1 (ref.)
>12	0.37 (0.18–0.75)	−405 (−1,206 to 396)	0.79 (0.48–1.29)	0.92 (0.71–1.20)
Continuous, per g/dl	0.79 (0.66–0.95)	−256 (−431 to −81)	0.95 (0.84–1.07)	0.94 (0.90–0.99)

Each column is a separate model adjusted for variables in table 3 with the exception of facility anemia management variables; accounting for facility clustering.

ESA dose is expressed in units/week.

OR (95% CI) for Hgb <9 g/dl (vs. ≥9) is 1.23 (0.97–1.57).

Restricted to patients on ESA use.